We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Database Provides First-Ever Map of Proteome Signature in Blood from Cancer Patients

By LabMedica International staff writers
Posted on 10 Jan 2023

Cancer prediction medicine has received a boost with the recent unveiling of a new cancer protein profile database compiled from AI and machine learning that enables identification of individual cancer types based on a drop of blood. More...

The new open-access Disease Blood Atlas produced by the Human Protein Atlas (Sweden) consortium provides a first-ever map of the proteome signature in blood from cancer patients. The Disease Blood Atlas highlights 1,463 proteins associated with 12 different types of cancer, and presents proteins that can be used to identify individual cancer types based on a drop of blood.

The Disease Blood Atlas was compiled from measurements of minute amounts of blood plasma collected from 1,400 cancer patients at the time of diagnosis and before treatment. The blood samples underwent a combination of statistical analysis of gene expression and machine-learning-based disease prediction. The release marks the 22nd version of the open-access Human Protein Atlas, a resource for profiling human proteins, which contains 12 sections each exploring the human proteins from different angles, including the new Disease Blood Atlas and the Protein 3-D Structure sections.

The release is accompanied by five million pages of updates in the Human Protein Atlas’ databases of tissues and cell lines. The Protein 3-D Structure section shows the 3-D structures for all human proteins using an AI-based prediction model (AlfaFold). In addition, a major update of the Tissue Atlas section provides detailed multiplex spatial profiling of proteins specific for human testis and kidney. More data is also provided on single cell analysis of tissues and organs, as well as data from an extensive catalogue of human cell lines.

“This is a novel pan-cancer strategy for exploring the proteome signature in blood from cancer patients,” said KTH Royal Institute of Technology Professor Mathias Uhlén who led the Human Protein Atlas consortium. “We believe that the new sections of the open access Human Protein Atlas with large amounts of novel data covering all human proteins provides new dimensions of valuable information for researchers interested in human biology and disease.”

Related Links:
Human Protein Atlas


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Gold Member
Platelet Function Analyzer
PL-12
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: WashU Medicine researchers found that dozens of blood proteins shift during Alzheimer’s treatment and may help monitor the effects of the medication. (Image Credit: Matt Miller/WashU Medicine)

Blood Biomarker Patterns Could Support Monitoring of Anti-Amyloid Treatment

Patients with early-stage Alzheimer’s disease may receive anti-amyloid therapy to clear amyloid protein deposits from the brain. These treatments can slow disease progression, but they do not cure the... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.